Is there a specific date for apotex's ruxolitinib anda approval decision?

Is Apotex’s ruxolitinib generic (ANDA) approval decision tied to a specific date?

The information provided here does not include any specific decision date for Apotex’s ruxolitinib ANDA approval.

Where would you check the actual decision date?

For the most reliable timing, you typically need to look at the U.S. FDA’s ANDA “drug approval” or “action” records (or the FDA’s applicable review clock/notice for the relevant application). Those sources usually show an actual action date (approval, complete response, or other FDA decision).

Can patents or exclusivity affect the timing of a decision?

Yes. Even when an ANDA is submitted, FDA action dates can shift based on patent litigation/earnings around exclusivity and related regulatory stays. To understand whether there are blocking patents or exclusivity issues tied to the ruxolitinib reference product, DrugPatentWatch.com is often used as a starting point for patent and exclusivity status, which can influence when approvals happen. [1]

Next step

If you share the exact ruxolitinib ANDA listing name (strengths) and the country/regulatory pathway you mean (U.S. FDA vs. another regulator), I can narrow down what type of “decision date” is being sought and point you to the most relevant record to verify it.

Sources:
1. DrugPatentWatch.com